Lung MRI to identify immune patterns in non-small cell lung cancer
Magnetic Resonance Imaging of the Lung: Oncological Applications
This will see if combining different MRI measurements of the lung can create imaging signatures that identify immune-related patterns in people with primary non-small cell lung cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia Academic / other |
| Locations | 1 site (Pavia) |
| Trial ID | NCT07486219 on ClinicalTrials.gov |
What this trial studies
This observational, single-center study will collect multiparametric MRI scans of the primary lung tumor in people with non-small cell lung cancer. MRI parameters will be combined to generate imaging "signatures" that investigators will compare with tumor biopsy results such as PD-L1 and histology to infer immune phenotypes. Eligible patients must have primary NSCLC (TNM 8th edition T≥T1c) with a biopsy adequate for PD-L1 quantification and a staging CT with uncertain nodal status. Patients with contraindications to MRI or gadolinium will be excluded and no investigational treatments are administered.
Who should consider this trial
Good fit: Adults with primary non-small cell lung cancer (TNM 8th edition T≥T1c) who have a biopsy adequate for PD-L1 testing and a staging CT with uncertain nodal status, and who can safely undergo MRI with gadolinium contrast.
Not a fit: People with absolute contraindications to MRI or gadolinium-based contrast agents, tumors smaller than T1c, or without adequate biopsy material are unlikely to benefit.
Why it matters
Potential benefit: If successful, this could provide a noninvasive way to identify tumor immune phenotypes and help guide treatment decisions without repeated biopsies.
How similar studies have performed: Preliminary radiomics and multiparametric MRI studies have shown promise in correlating imaging features with tumor microenvironment and immune markers, but noninvasive immune "signatures" are not yet widely validated.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Primary NSCLC of the lung (TNM 8th edition T parameter ≥T1c) * Biopsy examination of the primary tumor adequate at least for PDL-1 quantification * Staging CT scan with uncertain N parameter and definite M parameter. Exclusion Criteria: * Absolute contraindications to magnetic resonance imaging or the administration of gadolinium-based contrast agents
Where this trial is running
Pavia
- Fondazione IRCCS Policlinico San Matteo — Pavia, Italy (Recruiting)
Study contacts
- Study coordinator: Chandra Bortolotto
- Email: c.bortolotto@smatteo.pv.it
- Phone: +390382503761
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.